Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.72), $0.07 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $553 million versus the consensus estimate of $524.51 million.

GUIDANCE:

Exact Sciences sees FY2023 revenue of $2265-2315 million, versus the consensus of $2289 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.